<DOC>
	<DOCNO>NCT00222222</DOCNO>
	<brief_summary>Aims study find vascular marker inflammation endothelial damage course severe sepsis septic patient effect treatment anti-inflammatory medication ( Drotregocin alfa ( activate ) ) . Another aim find new marker gene polymorphisms prognosis mortality patient severe sepsis . The hypothesis high plasma concentration certain marker septic patient associate high mortality rate .</brief_summary>
	<brief_title>Mediators Inflammation , Prognostic Markers Genetic Polymorphisms Patients With Sepsis</brief_title>
	<detailed_description>During past year many investigator focus immunological change sepsis disease , great attention pay development practicable mean immunomonitoring . Human activate protein C ( Drotrecogin alfa ( activate ) ) , important coagulation inhibitor play major role regulate microvascular coagulation , inflammation immunology . Little known prognostic vascular biomarkers time course patient severe sepsis .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>SIRSCriteria Proven Infection One sepsisinduced organfailure Adults &lt; 18 year old Anemia Pregnancy Blood donor last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>severe sepsis</keyword>
	<keyword>prognostic marker</keyword>
	<keyword>polymorphism</keyword>
	<keyword>SIRS</keyword>
</DOC>